Paxlovid Boceprevir Intermediate CAS 565456-77-1 Assay ≥99.0%
Commercial Supply PF-07321332 Paxlovid Related Intermediates with High Quality
L-tert-Leucine (H-Tle-OH) CAS 20859-02-3
Caronic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride 565456-77-1
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane CAS 943516-54-9
Chemical Name | (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride |
Synonyms | Methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate Hydrochloride |
CAS Number | 565456-77-1 |
CAT Number | RF-PI318 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C9H15NO2.ClH |
Molecular Weight | 205.683 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White to Off-White Powder |
Identification A | IR: Similar to Reference Substance |
Identification B | Retention Time: Similar to Reference Substance |
Enantiomer | ≤0.15% |
Related Impurity (by HPLC) | |
Unknown Impurity | ≤0.20% |
Total Impurities | ≤1.0% |
Water | ≤0.50% |
Residue on Ignition | ≤0.10% |
Heavy Metals | ≤20ppm |
Assay | ≥99.0% |
Test Standard | Enterprise Standard |
Usage | Intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride (CAS 565456-77-1) is an azabicyclohexane derivative used in the preparation of hepatitis C virus (HCV) NS3 serine protease inhibitor. It's the intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0). PF-07321332 is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor . PF-07321332 targets to the SARS-CoV-2 virus and can be used for COVID-19 reseacrch. Boceprevir (INN, trade name Victrelis) is a protease inhibitor used as a treatment for hepatitis C genotype 1. It binds to HCV nonstructural 3 NS3 (HCV) active site. It was being developed by Schering-Plough, but is now being developed by Merck since Schering was acquired in 2009. It was approved by the FDA on May 13, 2011.